Autolus (United Kingdom)

Recent papers from Autolus (United Kingdom)

1. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaLeukemia · 2026
2. CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisScience Translational Medicine · 2026
3. Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domainsMolecular Therapy · 2026
4. CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX StudyCancer Research Communications · 2026
5. The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).Journal of Clinical Oncology · 2026
6. CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine · 2026
7. P157 Obecabtagene autoleucel, a CD19-targeting autologous chimeric antigen receptor T-cell therapy, in patients with severe, refractory systemic lupus erythematosus: Phase I CARLYSLE preliminary resultsLara D. Veeken · 2026
8. Validation of a Multiplexed Quantitative PCR Assay for Obecabtagene Autoleucel CAR T cell Expansion and Persistence MonitoringTransplantation and Cellular Therapy · 2026
9. Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-cell Therapy, in US Adults with B-ALLTransplantation and Cellular Therapy · 2026
10. Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)Transplantation and Cellular Therapy · 2026
11. Treatment of Pediatric Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia with Obecabtagene autoleucel, a CD19-Directed Chimeric Antigen Receptor T-cell Therapy: Preliminary Findings from the Phase Ib/II CATULUS TrialTransplantation and Cellular Therapy · 2026
12. Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)Blood · 2025
13. Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)Blood · 2025
14. The potential of microfluidic cell analysis in CAR T cell therapy manufacturingFrontiers in Bioengineering and Biotechnology · 2025
15. ARM’s Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path AheadJournal of Market Access & Health Policy · 2025
16. In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T‐Cell NeoplasmsHematological Oncology · 2024
17. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trialNature Medicine · 2024
18. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial2024
19. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.Journal of Clinical Oncology · 2024
20. Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometryBlood Cancer Journal · 2024